Back to search results

Intensive Neurorehabilitation for Pediatric Neurodevelopmental Disorders

This study is observing how a two-week intensive neurorehabilitation program helps children aged 4 to 12 with neurodevelopmental disorders like cerebral palsy, autism, and developmental delay. The program involves about 2.5 hours of individualized therapy per day, tailored to each child's specific needs, and may include activities like sensory integration and motor planning. Researchers are looking at how much a child's functional development improves from the beginning to the end of this two-week program. The study is currently unclear on its recruitment status and plans to include 100 participants.

Study design
This is an observational study, meaning researchers are watching and recording outcomes without introducing new treatments. It aims to include 100 participants.
What's involved
Participants will attend individualized therapy sessions for approximately 2.5 hours per day over a two-week period.
Compensation
Not stated in the trial record.
Follow-up
Functional development is measured from the start to the end of the two-week intensive program.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07493096

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

Recruiting
Not specifiedAges 4–12Observational
Healing Hope International
~100 participants
Updated 2026-03-25 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Clinician Assessed Functional Neurodevelopmental Performance
Measured over Baseline to end of 2 week intensive program

Conditions

Neurodevelopmental Disorders
Neurodevelopmental Disorders (NDD)
Neurodevelopmental Disorders and Developmental Abnormalities
Developmental Delay (Disorder)
Cerebral Palsy (CP)
Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment
Cerebral Palsy Infantile
Cerebral Palsy Spastic Hemiplegic
Cerebral Palsy, Dyskinetic
Autism Spectrum Disorder
Autism Spectrum Disorder (ASD
Hypoxic Ischemic Encephalopathy
Hypoxic Ischemic Encephalopathy (HIE)
Traumatic Brain Injury (TBI)
Sensory Processing Disorder
Chromosomal Abnormalities
Genetic Disorders
Down Syndrome (Trisomy 21)
Fragile X Syndrome (FXS)
RETT Syndrome With Proven MECP2 Mutation
Williams Syndrome
22q11.2 Deletion Syndrome
Sensorimotor Integration

Explore related trials

22q11.2 Deletion SyndromeAutism Spectrum DisorderCerebral PalsyDevelopmental DelayDown SyndromeFragile X SyndromeHypoxic Ischemic EncephalopathyNeurodevelopmental DisorderRett SyndromeSensory integration disorderTraumatic EncephalopathyWilliams Syndrome

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP · PRINCIPAL_INVESTIGATOR · Board Certified Pediatric Therapist Executive Director Ability and Beyond Integrated Therapies

Who to contact

Genelle Mills, OTR/L
[email protected]
(480) 620-4514
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pediatric participants between approximately 4 and 12 years of age at the time of enrollment.
Diagnosed with or presenting with neurodevelopmental, neurologic, or genetic conditions, including but not limited to:
cerebral palsy
autism spectrum disorder
developmental delay
hypoxic ischemic encephalopathy (HIE)
traumatic brain injury
sensory processing disorder
chromosomal or genetic abnormalities
Demonstrate functional impairments in one or more neurodevelopmental domains, including:
motor coordination or motor planning
sensory processing
attention or executive functioning
oculomotor or visual processing
communication
emotional or behavioral regulation
activities of daily living
Enrolled in and able to participate in a two-week intensive therapy program consisting of approximately 2.5 hours per day/ 5 days per week
Able to complete baseline and post-program clinical assessment using clinician-observed or caregiver-reported measures.
Parent or legal guardian able to provide informed consent and participate in reporting functional outcomes when applicable.

Exclusion

Medical instability or acute medical condition that would prevent safe participation in an intensive therapy program.
Severe uncontrolled seizure activity or other neurologic condition that would interfere with participation in structured therapeutic activities, as determined by the treating clinician.
Behavioral or psychological conditions that would prevent safe engagement in the therapy environment despite appropriate support.
Inability to attend or complete the full two-week intensive program.
Lack of sufficient baseline or post-intervention data to assess change in functional performance.
Concurrent participation in another structured intervention or clinical study that would confound interpretation of functional outcomes, at the discretion of the investigator.

What this trial measures

  • Change in Clinician Assessed Functional Neurodevelopmental PerformanceBaseline to end of 2 week intensive program

    Within participant change from baseline to completion of the 2 week intensive program in individualized clinician assessed neurodevelopmental performance domains used in routine care. Measures may include neural timing accuracy in milliseconds relative to metronome paced motor tasks, oculomotor performance scored by saccadic eye movements and horizontal pursuits, primitive reflex integration scored on a 0-5 scale, processing speed/visual scanning completion time, bilateral coordination, crossing midline, sustained attention duration, tactile or stimulation tolerance, executive functioning, emotional regulation, communication intent, and participation in non preferred activities. Each participant is assessed only on domains relevant to their presentation, consistent with the source document's individualized assessment model.